GlassScriptPhysician profile
Crystal Alack
NPI 1992116255
$1,576.14
in general payments reported to CMS, 2019-2025
16 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $679 · 2022: $465 · 2023: $287 · 2024: $23.67 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $431.31 | 2021-2023 | Liletta |
| Astellas Pharma US INC | $212.25 | 2023-2025 | Veozah |
| Avion Pharmaceuticals | $185.85 | 2021-2023 | Balcoltra |
| Therapeuticsmd, INC. | $169.54 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $130.54 | 2022-2023 | |
| Aspira Women'S Health INC | $85.39 | 2021 | |
| Scynexis, INC. | $78.79 | 2022 | |
| Organon LLC | $70.45 | 2021-2023 | Nexplanon |
| Novo Nordisk INC | $44.63 | 2022-2023 | Wegovy, Saxenda |
| Takeda Pharmaceuticals U.S.A., INC. | $44.06 | 2021-2023 | Trintellix |
| Agile Therapeutics, INC. | $32.07 | 2021 | |
| Evofem Biosciences, INC. | $28.57 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $19.27 | 2021 | |
| Millicent US INC | $17.41 | 2023 | Femring, Intrarosa |
| Pfizer INC. | $13.77 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Alack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.